Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab

Onkologie(Czech Republic)

Volumn 36, Issue 10, 2013, Pages 554-558

  Tonyali, Onder ^a   Coskun, Ugur ^a   Sener, Nur ^b   Inanc, Mevlude ^c   Akman, Tulay ^d   Ulas, Arife ^e   Yazilitas, Dogan ^f   Bal, Oznur ^g   Kucukoner, Mehmet ^h   Yildirim Ozdemir, Nuriye ⁱ   Demirci, Umut ^j   Gunaydin, Yusuf ^a   Yildiz, Ramazan ^b   Karaca, Halit ^c   Unal, Olcun Umit ^d   Gumus, Mahmut ^b   Benekli, Mustafa ^a   Buyukberber, Suleyman ^a  

^a GAZI UNIVERSITY   (Turkey)

^b DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^c ERCIYES UNIVERSITY   (Turkey)

^d DOKUZ EYLUL UNIVERSITY   (Turkey)

^e Ali Osman Sonmez Oncology Hospital   (Turkey)

^f Konya Numune Education and Research Hospital   (Turkey)

^g ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^h DICLE UNIVERSITY   (Turkey)

ⁱ ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^j ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

more..

Author keywords

Adjuvant treatment; Breast cancer; Early disease; HER2; Prognosis; Trastuzumab

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; HUMAN; LOADING DRUG DOSE; LYMPH NODE; MAJOR CLINICAL STUDY; MEDICAL RECORD; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREVALENCE; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; TURKEY; YOUNG ADULT;

EID: 84885585847     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000355156     Document Type: Article

References (19)

1. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-137.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182.
3. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
4. Boekhout AH, Beijnen JH, Schellens JH: Trastuzumab. Oncologist 2011;16:800-810.
5. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36.
6. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J: Adjuvant trastuzumab in HER2- positive breast cancer. N Engl J Med 2011;365: 1273-1283.
7. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N: Fouryear follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011;29:3366-3373.
8. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354:809-820.
9. Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Oksuzoglu B, Ozdemir NY, Yazilitas D, Benekli M, Uner A, Yamac D, Demirci U, Yildiz R, Karaca H, Unal OU, Bal O, Gumus M, Buyukberber S; Anatolian Society of Medical Oncology (ASMO): Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive earlystage breast cancer. J Cancer Res Clin Oncol 2012; 138:2145-2151.
10. Barbareschi M, Cuorvo LV, Girlando S, Bragantini E, Eccher C, Leonardi E, Ferro A, Caldara A, Triolo R, Cantaloni C, Decarli N, Galligioni E, Dalla Palma P: PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy. Virchows Arch 2012;461:129-139.
11. Jensen JD, Knoop A, Laenkholm AV, Grauslund M, Jensen MB, Santoni-Rugiu E, Andersson M, Ewertz M: PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 2012;23:2034-2042.
12. Costa RB, Kurra G, Greenberg L, Geyer CE: Efficacy and cardiac safety of adjuvant trastuzumabbased chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol 2010;21:2153-2160.
13. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB: Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 2011;29:4491-4497.
14. Jelovac D, Wolff AC: The adjuvant treatment of HER2-positive breast cancer. Curr Treat Options Oncol 2012;13:230-239.
15. Rodrigues MJ, Peron J, Frénel JS, Vano YA, Wassermann J, Debled M, Picaud F, Albiges L, Vincent-Salomon A, Cottu PH: Benefit of adjuvant trastuzumab-based chemotherapy in T1ab nodenegative HER2-overexpressing breast carcinomas: a multicenter retrospective series. Ann Oncol 2013; 24:916-924.
16. Gandhi S, Verma S: Early breast cancer in the older woman. Oncologist 2011;16:479-485.
17. Brollo J, Curigliano G, Disalvatore D, Marrone BF, Criscitiello C, Bagnardi V, Kneubil MC, Fumagalli L, Locatelli M, Manunta S, Goldhirsch A: Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. Cancer Treat Rev 2013;39:44-50.
18. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV: Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005;23:7721-7735.
19. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Iorfida M, Mazza M, Balduzzi A, Veronesi P, Luini A, Intra M, Goldhirsch A, Colleoni M: Progesterone receptor loss identifies luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol 2013;24:661-668.